PROPRANOLOL FOR PREVENTION OF RECURRENT GASTROINTESTINAL-BLEEDING IN PATIENTS WITH CIRRHOSIS - A CONTROLLED-STUDY
PROPRANOLOL FOR PREVENTION OF RECURRENT GASTROINTESTINAL-BLEEDING IN PATIENTS WITH CIRRHOSIS - A CONTROLLED-STUDY
复制标题
DOI：
10.1056/nejm198112033052302
复制
发表时间：
1981-01-01
影响因子：
158.5
通讯作者：
BENHAMOU, JP
中科院分区：
文献类型：
--
作者：
LEBREC, D;POYNARD, T;BENHAMOU, JP
因为普萘洛尔降低门静脉压力，它可以预防与门静脉高压相关的消化道出血。肝硬化患者（74例），因胃肠道出血入院，口服普萘洛尔剂量降低心率25%（38例）或安慰剂（36例）。普萘洛尔组和安慰剂组在研究后1年内无复发性胃肠道出血的患者比例分别为96%和50%（P < 0.0001）。持续口服普萘洛尔对预防肝硬化患者消化道再出血有效。
Because propranolol decreases portal venous pressure, it may prevent gastrointestinal bleeding associated with portal hypertension. Patients (74) with cirrhosis, admitted because of gastrointestinal bleeding, either oral propranolol in doses that reduced the heart rate by 25% (38 patients) or a placebo (36). The proportion of patients free of recurrent gastrointestinal bleeding 1 yr after the study was 96% in the propranolol group and 50% in the placebo group (P < 0.0001). Evidently continuous oral propranolol is effective in preventing recurrent gastrointestinal bleeding in cirrhosis patients.